Trials / Active Not Recruiting
Active Not RecruitingNCT06254807
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
An Open-Label, Single-Arm Study of Autologous Anti-HER2 Chimeric Antigen Receptor Monocytes (CT-0525), in Participants With HER2 Over Expressing Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Carisma Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-0525 | Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor |
Timeline
- Start date
- 2024-01-08
- Primary completion
- 2025-03-31
- Completion
- 2026-03-31
- First posted
- 2024-02-12
- Last updated
- 2024-12-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06254807. Inclusion in this directory is not an endorsement.